Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
40
ALDX Quote, Financials, Valuation and Earnings
Last price:
$4.87
Seasonality move
:
5.87%
Day range:
$4.81 - $5.02
52-week range:
$1.14 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.95x
Volume:
1.5M
Avg. volume:
766.2K
1-year change:
-1.61%
Market cap:
$293M
Revenue:
--
EPS (TTM):
-$0.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -47.25% | $9.67 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.26 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.96% | -57.14% | $27.25 |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.15 | -- | -22.97% | $22.00 |
|
EXEL
Exelixis, Inc.
|
$590.2M | $0.67 | 7.5% | 59.24% | $44.94 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
$4.87 | $9.67 | $293M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$25.88 | $29.26 | $4.4B | 16.65x | $0.00 | 0% | 4.16x |
|
ADMA
ADMA Biologics, Inc.
|
$19.72 | $27.25 | $4.7B | 23.16x | $0.00 | 0% | 9.93x |
|
AVXL
Anavex Life Sciences Corp.
|
$4.57 | $22.00 | $408.3M | -- | $0.00 | 0% | -- |
|
EXEL
Exelixis, Inc.
|
$44.01 | $44.94 | $11.8B | 18.53x | $0.00 | 0% | 5.50x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$5.27 | $11.75 | $311.4M | -- | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.800 | -- | 11.47x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.460 | 1.59% | 3.47x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Aldeyra Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ALDX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 25.76%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ALDX or ACAD?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 98.49%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.26 which suggests that it could grow by 13.07%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.5 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ALDX or ACAD More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock ALDX or ACAD?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ACAD?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 4.16x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ACADACADIA Pharmaceuticals, Inc.4.16x 16.65x $278.6M $71.8M
-
Which has Higher Returns ALDX or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 27.14%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About ALDX or ADMA?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 98.49%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 38.19%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.5 0 0 ADMAADMA Biologics, Inc.4 0 0 -
Is ALDX or ADMA More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock ALDX or ADMA?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ADMA?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 23.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 9.93x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ADMAADMA Biologics, Inc.9.93x 23.16x $134.2M $36.4M
-
Which has Higher Returns ALDX or AVXL?
Anavex Life Sciences Corp. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of --. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Anavex Life Sciences Corp.'s return on equity of -44.87%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M -
What do Analysts Say About ALDX or AVXL?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 98.49%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 381.4%. Given that Anavex Life Sciences Corp. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.5 0 0 AVXLAnavex Life Sciences Corp.2 1 0 -
Is ALDX or AVXL More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.531%.
-
Which is a Better Dividend Stock ALDX or AVXL?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or AVXL?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Anavex Life Sciences Corp. quarterly revenues of --. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M
-
Which has Higher Returns ALDX or EXEL?
Exelixis, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 32.38%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About ALDX or EXEL?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 98.49%. On the other hand Exelixis, Inc. has an analysts' consensus of $44.94 which suggests that it could grow by 2.12%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Exelixis, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.5 0 0 EXELExelixis, Inc.9 9 0 -
Is ALDX or EXEL More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.
-
Which is a Better Dividend Stock ALDX or EXEL?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or EXEL?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 18.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 5.50x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M EXELExelixis, Inc.5.50x 18.53x $597.8M $193.6M
-
Which has Higher Returns ALDX or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -40.15%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ALDX or VNDA?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 98.49%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.5 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ALDX or VNDA More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.831, which suggesting that the stock is 16.879% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock ALDX or VNDA?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or VNDA?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M VNDAVanda Pharmaceuticals, Inc.1.46x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
